我要投票 半边天NEWOMEN在乌鸡白凤丸行业中的票数:262
· 外 推 电 报 ·
2025-05-04 10:29:48 星期日

【半边天NEWOMEN是哪个国家的品牌?】

半边天NEWOMEN是什么牌子?「半边天NEWOMEN」是 江西半边天药业有限公司 旗下著名品牌。该品牌发源于香港,由创始人翁汉辉在1998-04-14期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力半边天NEWOMEN品牌出海!将品牌入驻外推网,定制半边天NEWOMEN品牌推广信息,可以显著提高半边天NEWOMEN产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

始于1998年,香港半边天药业国际集团旗下,专注妇科中成药、保健品的研发、生产、销售的制药公司


半边天药业国际集团(香港)有限公司成立于一九九八年四月,目前拥有江西半边天药业有限公司、深圳市半边天保健品有限公司、深圳市金药坊医药有限公司等多家下属企业,并在江西省泰和经济开发区建有占地十六万余平方米的生产基地——半边天药业国际集团工业城,固定资产规模达人民币2亿多元,其国内总部设在深圳。

半边天药业国际集团本着“专心造好药,健康半边天”的经营宗旨,专注妇科中成药、保健品的研发、生产、销售,已形成具有调经类、乳腺类、补血类、消炎类、排毒类等多种功能的妇科产品线,主要品种有国家中药保护品种和新药复方乌鸡口服液、乳宁丸、阿胶益寿口服液、乌鸡白凤丸、芦荟胶囊、妇舒洁洗液、妇炎康片等。

半边天药业国际集团下属的成员企业江西半边天药业拥有:口服液、糖浆、蜜丸、水丸、洗液等多条具有国内专业水平的生产线;生产能力10亿元以上;2004年和2009年两次通过国家药监局的GMP认证。目前正在建设中的二期工程包括了片剂、胶囊剂、颗粒剂等多种剂型。二期工程预计2012年完工建成。

半边天药业国际集团坚持以市场为导向,下属成员企业深圳金药坊医药有限公司是集团公司的营销中心,已于二OO四年六月顺利通过GSP认证,目前已建成以深圳为中心,辐射华南、华东、中南、西南的销售网络,在广东、广西、云南、贵州、湖南、湖北、重庆、四川、江苏、江西、安徽、浙江、山东等二十多个省、直辖市、自治区设立了二百多个营销分支机构,建立了一千多人的专业销售队伍。

半边天药业国际集团注重科技创新,与国内外多家医药研究机构建立了密切合作关系,实现了产品研发、信息交流、市场开拓、人才培养友好互动,生产、储备、研制、构想齐头并进的良好发展格局。

未来,半边天药业国际集团将继续“专业妇科品牌”的道路,通过并购、合作等多种途径,丰富产品群,扩大销售规模,进一步提升品牌影响力,积极寻求上市,实现中国医药市场妇科品牌的战略目标。


英文翻译:Started in 1998, half sky Pharmaceutical International Group (Hong Kong) Co., Ltd., a pharmaceutical company under half sky Pharmaceutical International Group in Hong Kong, which focuses on the research and development, production and sales of Chinese medicine for gynecology and health care products, was founded in April 1998. At present, it has Jiangxi half sky Pharmaceutical Co., Ltd., Shenzhen half sky health care products Co., Ltd., Shenzhen Golden Pharmaceutical Co., Ltd., etc There are more than 160000 square meters of production base - banbiantian Pharmaceutical International Group Industrial City in Taihe Economic Development Zone of Jiangxi Province, with fixed assets of more than 200 million yuan. Its domestic headquarters is located in Shenzhen. Based on the business tenet of "concentrate on making medicine, healthy half sky", banbiantian Pharmaceutical International Group focuses on the R & D, production and sales of Chinese traditional medicine and health care products in gynecology. It has formed a gynecology product line with multiple functions such as menstrual regulation, breast, blood tonic, anti-inflammatory, detoxification, etc. the main varieties are national traditional Chinese medicine protection varieties and new compound Wuji oral liquid, runing pill, a Jiaoyishou oral liquid, Wuji Baifeng pill, aloe capsule, fushujie lotion, Fuyankang tablet, etc. Jiangxi banbiantian Pharmaceutical Co., Ltd., a member enterprise of banbiantian Pharmaceutical International Group, has many production lines with domestic professional level, such as oral liquid, syrup, honey pill, water pill, lotion, etc.; the production capacity is more than 1 billion yuan; in 2004 and 2009, it passed the GMP certification of the State Food and Drug Administration twice. At present, the second phase project under construction includes tablet, capsule, granule and other dosage forms. The second phase of the project is expected to be completed in 2012. Banbiantian Pharmaceutical International Group adheres to the market orientation, and its subordinate member company Shenzhen jinyaofang Pharmaceutical Co., Ltd. is the marketing center of the group company. It has successfully passed the GSP certification in June 2004. At present, it has established a sales network with Shenzhen as the center, radiating South China, East China, Central South China and southwest China. It is located in Guangdong, Guangxi, Yunnan, Guizhou, Hunan, Hubei, Chongqing and Siyuan Sichuan, Jiangsu, Jiangxi, Anhui, Zhejiang, Shandong and more than 20 provinces, municipalities and autonomous regions have set up more than 200 marketing branches and established a professional sales team of more than 1000 people. Banbiantian Pharmaceutical International Group attaches great importance to scientific and technological innovation, and has established close cooperation with a number of pharmaceutical research institutions at home and abroad. It has achieved a good development pattern of product research and development, information exchange, market development, friendly interaction of talent training, and simultaneous development of production, reserves, research and ideas. In the future, banbiantian Pharmaceutical International Group will continue to be a "professional gynecological brand", enrich the product group, expand the sales scale, further enhance the brand influence, actively seek listing, and achieve the strategic goal of gynecological brand in China's pharmaceutical market through M & A, cooperation and other ways.

本文链接: https://www.waitui.com/brand/fae4e258c.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

美国4月关税收入超170亿美元

当地时间5月3日,据雅虎财经报道,美国特朗普政府在4月份征收了超过174亿美元的“关税和某些消费税”。报道称,这几乎是3月份96亿美元收入的两倍,也远超特朗普第一任期内的任何收入。自1月1日以来,这些关税已累计为政府注入了超过700亿美元的收入。特朗普此前在节目中表示,随着数十亿美元的关税收入涌入,美国“才刚刚开始”。

30分钟前

伯克希尔哈撒韦Q1净利润降至46亿美元,同比减少64%

伯克希尔哈撒韦第一季度净利润46.03亿美元,同比减少64%,上年同期盈利127.02亿美元;第一季度营收897.25亿美元,上年同期898.69亿美元;第一季度投资净亏损50.38亿美元,上年同期盈利14.8亿美元。

30分钟前

巴菲特谈巨额现金储备

巴菲特在伯克希尔・哈撒韦股东大会上表示,伯克希尔现金数量确实是相当高,但好的机会不会每一天都出现。不正确或不正当的投资,反而会损害投资人的利益。巴菲特表示,他一直在寻找投资机会,并希望减少手头现金——可能降至500亿美元。事情偶尔会变得极具吸引力。重大交易“极不可能”明天就发生,但在五年内则并非如此。之所以赚了很多钱,是因为从未全仓投资。

30分钟前

巴菲特评价苹果CEO:“库克为伯克希尔赚的钱,比我为伯克希尔哈撒韦赚的还多。”

巴菲特在伯克希尔・哈撒韦股东大会上提到库克称,很高兴苹果CEO库克先生也到场了,在乔布斯逝世之后,库克接手苹果同样做得非常出色,没有人能像乔布斯一样,但库克对苹果也有很大建树。巴菲特打趣道,“说来有点难为情,库克为伯克希尔赚的钱,比我为伯克希尔哈撒韦赚的还多。”

30分钟前

年轻投资者如何塑造投资理念?巴菲特:与更优秀的人为伍

谈及年轻投资者应该如何塑造他们的投资理念时,巴菲特表示,你交往的人非常重要。“你应该和比你优秀的人在一起,”他说。“你会朝着你所交往的人的方向前进。”

30分钟前

本页详细列出关于半边天NEWOMEN的品牌信息,含品牌所属公司介绍,半边天NEWOMEN所处行业的品牌地位及优势。
咨询